{"retracted":false,"update":{"timestamp":1420502400000,"doi":"10.1212/01.wnl.0000459892.11490.a1","type":"correction"},"doi":"10.1212/wnl.0000000000000926","journal":"Neurology","publisher":"Ovid Technologies (Wolters Kluwer Health)","title":"CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS"}
